CMS advises Abris CEE Mid-Market III LP on its investment in ITP S.A., operating in the aesthetic medicine industry. The fund, through its subsidiary NEPT Holdings S. a r.l., signed the share purchase agreement relating to the acquisition of a strategic stake in ITP. S.A. from its founders.
Abris Capital Partners has been managing private equity funds since 2006. According to Abris, the acquisition of shares in ITP S.A. is the fifth investment from the EUR 500 million fund secured in autumn 2017 from international investors.
ITP S.A. specializes in the provision of state-of-the-art technology and global brands in the area of aesthetic medicine, medical devices and wellness equipment. It owns the Neauvia brand – the new generation of tissue fillers with hyaluronic acid and professional cosmeceutical lines, sold in more than 45 countries.
The private equity fund is being advised by an international team of CMS lawyers including Rafał Zwierz and Graham Conlon (partners) and Olga Czyżycka, senior associate. In addition to experts from the Warsaw office, the team includes transactional lawyers from CMS’s Milan, Geneva and Berlin offices.